Bio-genome big data company EDGC is developing various customized medical services. Based on bioinformatics (BI) technology, it analyzes individual genomes to predict the likelihood of disease onset and provides customized diagnostic testing services based on genetic information.
Its main businesses include non-invasive prenatal testing (NIPT), hereditary cancer testing, newborn genetic disorder testing, customized disease prediction testing, specialized genetic analysis testing for ophthalmic diseases, direct-to-consumer (DTC) genetic testing, and DNA app development. The company independently possesses the core technologies required in these testing service fields.
Patent attorney Eom Jeonghan of BLT Patent Law Firm reviewed EDGC’s patent and trademark application status.
Listed companies on the domestic stock market disclose patent acquisition facts through the Financial Supervisory Service’s electronic disclosure system. However, many stock investors tend to overlook patent disclosures.
Not only patents but also trademark registrations indicate the future direction of listed companies, making them one of the important indicators for assessing future corporate value. Some patent disclosures even act as direct triggers for stock price increases.
It is not easy for general investors to understand the impact on companies through patent disclosures or to check trademark application statuses one by one. Asia Economy, together with patent attorney Eom Jeonghan of BLT Patent Law Firm, is reviewing the patent and trademark application statuses of listed companies through the 'Special Express Train'.
The Special Express Train is an abbreviation for a broadcast that diligently searches for stocks surging due to patents.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
